Product Description
Our lead candidate OPS-121 targets the aggressive hematological disease acute myeloid leukemia (AML) and provides strong evidence for an effective elimination of CD33-positive AML cells caused by multiple effector cells. OPS-121 further comes along with an improved safety profile due to the low affinity binding of SIRPα to CD47 which limits unwanted CD47-related side effects. An additional pipeline candidate, OPS-301, targets solid tumors such as pancreatic and ovarian cancer. (Sourced from: https://www.opsyon.genzentrum.uni-muenchen.de/index.html)
Mechanisms of Action: CD33 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Opsyon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|